Winway Health Desk
On the agenda for INVEST Digital Health virtual Day 1: Hospital...
INVEST Digital Health virtual kicks off today and runs through September 25. At MedCity INVEST Digital Health virtual, you’ll hear from leading physician executives, payers, active investors...
ESMO: Lilly’s Verzenio pressures Pfizer with practice-changing win in early breast...
Ibrance has been leading the CDK4/6 inhibitor race thanks to its first-to-market status. But Eli Lilly’s Verzenio has now shown it could go where...
Amgen publishes, presents data on therapy with ‘undruggable’ target
Biotech giant Amgen is touting lung cancer data on its drug from an emerging class of small-molecule oncology therapeutics in a new publication and...
The HCD 10: Mark Chrisman, Building Professional
Who he is: A professional engineer with a doctorate in engineering, Mark Chrisman, PhD, PE, guides the healthcare practice for Henderson Engineers as well...
PHOTO TOUR: Behavioral Health Center Taube Pavilion
El Camino Health (ECH; Mountain View, Calif.) wanted to provide a safe and comfortable healing environment where patients are treated for mental health conditions...
Roche drug that previously failed in Covid-19 pneumonia shows efficacy in...
An autoimmune drug that failed in a previous clinical trial to improve conditions for patients with severe Covid-19 has shown efficacy in a second...
2020 may be the year from hell, but health tech IPO...
On top of the ongoing Covid-19 pandemic, 2020 has been punctuated by devastation: raging wildfires, record unemployment and growing inequality. But despite all of...
Mitigating the impact of Covid-19 on Medicare Advantage risk scores and...
Delays in care due to Covid-19 will likely lead to reduced risk scores for Medicare Advantage (MA) patients, lowering plan payments in 2021. For...
ESMO: Novartis parses long-awaited survival data for breast cancer blockbuster hopeful...
When Novartis won FDA approval for its breast cancer drug Piqray in HR-positive/HER2-negative patients with PIK3CA mutations last year, early survival data was impressive:...
AstraZeneca’s targeted lung cancer med Tagrisso slashes CNS recurrence by 82%
Once EGFR-mutated lung cancer spreads to the brain, a patient’s prognosis dramatically worsens. And that’s what AstraZeneca’s Tagrisso is trying to prevent in postsurgery...
